**ROTAVAC** (116E) is an oral vaccine, marketed under the brand name Vaxibaby in India. It is a live attenuated vaccine prepared from the G1P[8] strain of rotavirus. The vaccine is administered in a series of oral doses, typically three times, starting at 6 weeks of age. The vaccine is effective in preventing severe rotavirus gastroenteritis, which can be a leading cause of childhood morbidity and mortality in developing countries.

**DBT, NIAID/NIH** in 1987 and May 2013 funded research on the development and evaluation of the Vaxibaby vaccine. The vaccine was developed by the Indian Council of Medical Research (ICMR) and is currently being manufactured by the Serum Institute of India (SII). The vaccine is approved for use in India and is recommended for all infants by the World Health Organization (WHO).

**ROTAVAC** is a product of the Indian Council of Medical Research (ICMR), in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Communicable Diseases (NICD) in India. The vaccine is marketed by the Serum Institute of India (SII) and is distributed through the Indian Immunization Program (IIP). The vaccine is also approved by the Indian Council of Medical Research (ICMR) for use in children aged 6 weeks to 2 years.

**CDC** and PATH have been involved in the development and implementation of rotavirus vaccination programs in various countries, including India. The vaccine is widely used in India and is recommended for all infants by the Indian Immunization Program (IIP). The vaccine is also approved by the Indian Council of Medical Research (ICMR) for use in children aged 6 weeks to 2 years.

**DBT, NIAID/NIH** in 1987 and May 2013 funded research on the development and evaluation of the Vaxibaby vaccine. The vaccine was developed by the Indian Council of Medical Research (ICMR) and is currently being manufactured by the Serum Institute of India (SII). The vaccine is approved for use in India and is recommended for all infants by the World Health Organization (WHO).

**ROTAVAC** is a product of the Indian Council of Medical Research (ICMR), in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Communicable Diseases (NICD) in India. The vaccine is marketed by the Serum Institute of India (SII) and is distributed through the Indian Immunization Program (IIP). The vaccine is also approved by the Indian Council of Medical Research (ICMR) for use in children aged 6 weeks to 2 years.
1998: VAP occurs in new patients, and all patients having VAP are managed according to the institutional protocol. Patients with VAP are monitored, and antibiotic therapy is initiated. The institutional protocol includes the following steps:

- **Diagnosis:** VAP is diagnosed based on clinical and radiological findings.
- **Treatment:** Antibiotics are started immediately.
- **Monitoring:** Temperature, oxygen saturation, and other vital signs are monitored regularly.
- **Follow-up:** Patients are reviewed daily to assess response to therapy.

**2000s:** The institutional protocol is further refined to include a multidisciplinary approach involving nurses, physicians, and infection control specialists. CDC, NIH, AIIMS, and other institutions provide guidelines and support.

**2003:** The protocol is updated to include the use of new antibiotics and techniques. AIIMS, CDC, PATH, and other institutions continue to monitor the effectiveness of the protocol. NIAID and other institutions contribute to the development of new guidelines.

**2008:** The protocol is improved to include more rigorous monitoring and antibiotic stewardship.

**116E, I321:** The protocol is further refined to include the use of new technologies and techniques. AIIMS and other institutions continue to monitor the effectiveness of the protocol.

**2001:** The protocol is reviewed and updated to include the latest guidelines and research findings.

**2003:** The protocol is updated to include the use of new antibiotics and techniques. AIIMS and other institutions continue to monitor the effectiveness of the protocol.

**2008:** The protocol is improved to include more rigorous monitoring and antibiotic stewardship.

**116E:** The protocol continues to evolve, incorporating new technologies and techniques.

**2001:** The protocol is reviewed and updated to include the latest guidelines and research findings.

**2003:** The protocol is updated to include the use of new antibiotics and techniques. AIIMS and other institutions continue to monitor the effectiveness of the protocol.

**2008:** The protocol is improved to include more rigorous monitoring and antibiotic stewardship.

**116E:** The protocol continues to evolve, incorporating new technologies and techniques.
1b/2a 2018 2008 DBT, FFU, PATH, SAS, NIH, FFU, DBT, PATH, SAS

16E "ROAVAC®" 2018 "ROAVAC®" 2008 DBT, FFU, PATH, SAS, NIH, FFU, DBT, PATH, SAS, NIH.
ROTORVAC® ஆற்றம் தன்மை அளித்துள்ளது. ஆற்றம் மீது நோயை தானோரின் மருந்தை தரும் முடிவுகள் உண்டு. ஆற்றத் தொற்றை நோயை தானோரின் மருந்தை தரும் முடிவுகள் உண்டு. மேலும் அவ்விரு தொற்றை நோயை தானோரின் மருந்தை தரும் முடிவுகள் TNF, DBT, NIH, AIIMS, CDC, என்று பெரும்பாலும் உற்று மேலும் 116E செயல்துறை செயல்துறை ஆற்றத் தொற்றை நோயை தானோரின் மருந்தை தரும் முடிவுகள். அவ்விரு தொற்றை நோயை தானோரின் மருந்தை தரும் முடிவுகள் உண்டு. மேலும் 116E செயல்துறை செயல்துறை ஆற்றத் தொற்றை நோயை தானோரின் மருந்தை தரும் முடிவுகள்

http://www.defeatdd.org/rotavac-clinical-trial-results

ஏழு முறையிலும் சமாதியானது: http://dbtindia.nic.in

ஏழு முறையிலும் சமாதியானது: http://www.bharatbiotech.com

முனாவது குறிப்பிட்டுறை

ஏழு முறையிலும் சமாதியானது: Dr T.S. Rao, +91 (98) 7348-3538, tsgo@dbt.nic.in

ஏழு முறையிலும் சமாதியானது: முரலி, +91 98851 09594, Murali@enrightpr.com

ஏழு முறையிலும் சமாதியானது: சீலா, +91 98851 09594, Sheela@enrightpr.com
PATH మహాపారం సంస్థ నియంత్రణ: NIH and CDC నియంత్రణ: సమావేశ నిషేధం, +91 (97) 1724-3131, smalaviya@path.org

ఖండిత ఎస్టిసెట్స్ ప్రత్యేక సంశాంతి సాధనాలు:

Guillermo Meneses, GMMB, +1-202-445-1570, Guillermo.Meneses@gmmb.com
Allison Clifford, PATH, +1-202-669-7238, aclifford@path.org